Data protection Impressum

Biotech

Vaud-based biopharma Oculis has secured USD 59 million to extend operations into 2026, following a successful listing on NASDAQ Iceland Main Market.

Oculis announces completion of oversubscribed USD 59 million registered direct offering

15 April 2024

Geneva's Addex Therapeutics has teamed up with Perceptive Advisors to launch spin-off Neurosterix, a new player in neurology-focused drug development.

Addex Therapeutics launches spin-off Neurosterix in Geneva with USD 63 million investment

9 April 2024

Top Stories Western Switzerland

Top Stories from Western Switzerland (March 2024)

26 March 2024

The ARTORG team investigates how a special balloon catheter must be used so that drugs can reach and dissolve blood clots in the smallest branches. To do this, they combine engineering know-how, fluid mechanics and biological expertise.

Bern researchers unveil groundbreaking cardiac care method

19 March 2024

Alithea Genomics, which emerged from the EPFL in 2020, has distinguished itself within the life sciences sector with its cutting-edge RNA sequencing solutions.

Alithea Genomics embarks on next-phase growth with CHF 2.8 million funding

18 March 2024

Top Stories Western Switzerland

Business environment

Top Stories from Western Switzerland (February 2024)

27 February 2024

This significant financial backing underscores the potential of Alys's comprehensive pipeline targeting a broad spectrum of dermatological indications, from atopic dermatitis to psoriasis.

Alys Pharmaceuticals launches in Geneva with USD 100 million investment

19 February 2024

The breakthrough comes from the University's Autophagy Laboratory, where Prof. Patricia Boya and her team, in collaboration with the Spanish Margarita Salas Center for Biological Research (CIB-CSIC), have demonstrated the potential of specific drugs to stimulate mitophagy, thereby enhancing the ability of cells to "clean house" even as they age.

University of Fribourg discovers drug to combat age-related neuroinflammation

12 February 2024

GeNeuro‘s mission is to leverage HERV biology to develop safe and effective treatments for the benefit of patients, by neutralizing causal factors encoded by HERVs that represent 8% of human DNA.

GeNeuro secures EUR 5 million to advance post-COVID and neurodegenerative disease treatments

5 February 2024

In 2023, Swiss start-ups faced a challenging investment climate, marked by a significant reduction in venture capital funding.

Swiss start-ups raised CHF 2.6 billion in 2023

30 January 2024

1 … 5 6 7 8 9 10 11 12 13 … 22